Literature DB >> 24555821

Identification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: in vivo and in vitro evidence.

Hongming Liu1, Hua Sun, Danyi Lu, Yuchen Zhang, Xingwang Zhang, Zhiguo Ma, Baojian Wu.   

Abstract

1. The natural polyphenol gossypol possesses many therapeutic benefits. Here we aim to determine the elimination pathways of gossypol in vivo and in vitro. 2. Metabolite elucidation of gossypol was performed using UPLC-QTOF/MS coupled with Metabolynx analysis. Clearance of gossypol was evaluated in bile duct cannulated rats and in the single-pass perfused rat intestine model. In vitro glucuronidation of gossypol was characterized using liver and intestine microsomes as well as recombinant UDP-glucuronosyltransferase (UGT) enzymes. 3. Analysis of rat plasma, urine, and feces revealed glucuronidation as the only metabolic pathway for gossypol. In bile duct cannulated rats, considerable amounts of glucuronides (G1, G2 and G3; 58.8-83.2% of dose) and parent compound (5.0-20%) were excreted into bile after IV administration. In the perfused rat intestine model, gossypol was well absorbed with a [Formula: see text] (the dimensionless effective permeability) value of 4.4. Significant amounts of glucuronides (G1, G2 and G3) were excreted into the gut lumen (2.5%) and into the bile (4.8%). Biliary excretion of unchanged gossypol (6.0%) was comparable to that of glucuronides. Further, gossypol was subjected to rapid glucuronidation by liver and intestine microsomes. Reaction phenotyping showed that multiple UGT1A enzymes (including UGT1A1, 1A3, 1A7 and 1A8) are mainly responsible for gossypol metabolism. 4. In conclusion, glucuronidation was the only metabolic pathway for gossypol in rats. Excretion of unchanged gossypol into bile was also an important clearance mechanism.

Entities:  

Keywords:  Biliary excretion; UGT; UPLC-QTOF/MS; glucuronidation; gossypol

Mesh:

Substances:

Year:  2014        PMID: 24555821     DOI: 10.3109/00498254.2014.891780

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  9 in total

1.  Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.

Authors:  Fan Wang; Ming-Xing Miao; Bin-Bin Sun; Zhong-Jian Wang; Xian-Ge Tang; Yang Chen; Kai-Jing Zhao; Xiao-Dong Liu; Li Liu
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

2.  Role of the CLOCK protein in liver detoxification.

Authors:  Mengjing Zhao; Huan Zhao; Jiangming Deng; Lianxia Guo; Baojian Wu
Journal:  Br J Pharmacol       Date:  2019-12-28       Impact factor: 8.739

3.  Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.

Authors:  Xingwang Zhang; Tianpeng Zhang; Yali Lan; Baojian Wu; Zhihai Shi
Journal:  AAPS PharmSciTech       Date:  2015-07-18       Impact factor: 3.246

4.  Glucose-Based Mesoporous Carbon Nanospheres as Functional Carriers for Oral Delivery of Amphiphobic Raloxifene: Insights into the Bioavailability Enhancement and Lymphatic Transport.

Authors:  Yanghuan Ye; Tianpeng Zhang; Wan Li; Hua Sun; Danyi Lu; Baojian Wu; Xingwang Zhang
Journal:  Pharm Res       Date:  2015-11-09       Impact factor: 4.200

5.  Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug: formulation and pharmacokinetic evaluation.

Authors:  Yuchen Zhang; Xingwang Zhang; Hongming Liu; Shaohui Cai; Baojian Wu
Journal:  Int J Nanomedicine       Date:  2015-02-26

6.  Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112.

Authors:  Dong Dong; Xiao Wang; Huailing Wang; Xingwang Zhang; Yifei Wang; Baojian Wu
Journal:  Int J Nanomedicine       Date:  2015-03-31

7.  Regioselective Glucuronidation of Diosmetin and Chrysoeriol by the Interplay of Glucuronidation and Transport in UGT1A9-Overexpressing HeLa Cells.

Authors:  Xuejun Zeng; Jian Shi; Min Zhao; Qingwei Chen; Liping Wang; Huangyu Jiang; Feifei Luo; Lijun Zhu; Linlin Lu; Xinchun Wang; Zhongqiu Liu
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

8.  Metabolite Profiling, Pharmacokinetics, and In Vitro Glucuronidation of Icaritin in Rats by Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry.

Authors:  Beibei Zhang; Xiaoli Chen; Rui Zhang; Fangfang Zheng; Shuzhang Du; Xiaojian Zhang
Journal:  J Anal Methods Chem       Date:  2017-07-10       Impact factor: 2.193

Review 9.  Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials.

Authors:  Olga Renner; Mascha Mayer; Christian Leischner; Markus Burkard; Alexander Berger; Ulrich M Lauer; Sascha Venturelli; Stephan C Bischoff
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.